Avalo Therapeutics
AVTX
AVTX
24 hedge funds and large institutions have $159K invested in Avalo Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
82% less capital invested
Capital invested by funds: $863K → $159K (-$704K)
Holders
24
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$34K | |
| 2 | +$19.8K | |
| 3 | +$18.1K | |
| 4 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
+$10K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.35K |
Top Sellers
| 1 | -$444K | |
| 2 | -$198K | |
| 3 | -$15.7K | |
| 4 |
Millennium Management
New York
|
-$12.1K |
| 5 |
JPMorgan Chase & Co
New York
|
-$4.62K |